According to a new study published by Polaris Market Research, the global eClinical solutions market is anticipated to reach over USD 12,985 million by 2026. In 2017, the CTMS segment dominated the global market, in terms of revenue. In 2017, North America accounted for the majority share in the global eClinical solutions market.
Technological advancements in eClinical software such as use of cloud computing to secure the data and improve accessibility across remote locations are expected to boost the market growth. Cloud based solution software dominated the global market in 2017, owing to the ease of delivery and convenience of upgrading to advanced versions. This segment has been gaining traction in the recent years, and is expected to grow at the fastest rate during the forecast period.
Get Sample copy of this report: https://www.polarismarketresearch.com/industry-analysis/eclinical-solutions-market/request-for-sample
Several pharmaceutical organizations have deployed eClinical solution software to comply with the norms of the regulatory bodies for processing clinical data without errors and without any scope for manipulation. According to the ALCOA standard, the use of electronic clinical outcome assessments (eCOA) is essential in clinical trials, as these use smartphones, tablets, and personal computers to allow patients, clinicians, and their caregivers to directly report outcomes, which ensure highly productive data for better understanding of patient experience and faster approval process.
Among end users, the CROs segment is expected to grow at the fastest rate due to the ongoing trend of outsourcing clinical research operations to these third party organizations to save time and cost. As most of the drugs that have cleared Phase III clinical trials can be marketed under FDA norms with proper recommendations and guidelines through a new drug application (NDA), a majority of the drugs across the globe are in this phase of clinical research. Hence, most of the clinical data management systems were used for conducting phase III clinical trials.
The key players profiled in the report are Oracle Corporation, Parexel International Corporation, Medidata Solution, Inc., DataTrak International, Inc., CRF Health, OmniComm Systems, BioClinica Inc., eResearch Technology, eClinical Solutions, Inc., and PHT Corporation. The prominent players operating in the industry have adopted various strategies such as mergers and acquisition, product innovation and expansion, and R&D of innovative products.
Request For Discount: https://www.polarismarketresearch.com/industry-analysis/eclinical-solutions-market/request-for-discount-pricing
About Polaris Market Research
Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises. We at Polaris are obliged to serve our diverse customer base present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world
Contact us
Polaris Market Research
Phone: 1-646-568-9980
Email: [email protected]
Web: www.polarismarketresearch.com
According to a new study published by Polaris Market Research, the global eClinical solutions market is anticipated to reach over USD 12,985 million by 2026.
In 2017, the CTMS segment dominated the global market, in terms of revenue.
Government organizations across the globe have implemented stringent guidelines to obtain error-free authentic clinical data due to the burgeoning number of clinical data research.
Request for a sample of this research report @ https://www.polarismarketresearch.com/industry-analysis/eclinical-solutions-market/request-for-sample The governments of various countries across the globe have sanctioned funds to promote clinical research of novels drugs.
The adoption of clinical data management systems has increased in the recent years to process the queueing molecules in the development phase of clinical research.
This segment has been gaining traction in the recent years, and is expected to grow at the fastest rate during the forecast period.
New York, NY 19 May 2021: According to a new study published by Polaris Market Research, the global eClinical solutions market is anticipated to reach over USD 12,985 million by 2026.
In 2017, the CTMS segment dominated the global market, in terms of revenue.
In 2017, North America accounted for the majority share in the global eClinical solutions market.
Government organizations across the globe have implemented stringent guidelines to obtain error-free authentic clinical data due to the burgeoning number of clinical data research.
The governments of various countries across the globe have sanctioned funds to promote clinical research of novels drugs.
The adoption of clinical data management systems has increased in the recent years to process the queueing molecules in the development phase of clinical research.
According to a new study published by Polaris Market Research, the global eClinical solutions market is anticipated to reach over USD 12,985 million by 2026.
In 2017, the CTMS segment dominated the global market, in terms of revenue.
Government organizations across the globe have implemented stringent guidelines to obtain error-free authentic clinical data due to the burgeoning number of clinical data research.
Request for a sample of this research report @ https://www.polarismarketresearch.com/industry-analysis/eclinical-solutions-market/request-for-sample The governments of various countries across the globe have sanctioned funds to promote clinical research of novels drugs.
The adoption of clinical data management systems has increased in the recent years to process the queueing molecules in the development phase of clinical research.
This segment has been gaining traction in the recent years, and is expected to grow at the fastest rate during the forecast period.
Psychedelic drug stocks are showing incredible results and recovery in mental health patients without long-lasting side effects.
Many drug candidates are even showing promise in severe depression, PTSD, etc.
